Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2017

View Archived Issues

ADV-7103 granted E.U. orphan drug designation for distal renal tubulopathy acidosis

RDD Pharma's RDD-0315 given orphan drug status in E.U.

FDA grants orphan drug designation to BHV-5000 for Rett syndrome

Difolta approved in Japan for peripheral T-cell lymphoma

Trillium Therapeutics identifies EGFR inhibitor

Hypomorphic CARD11 mutations identified in patients with severe atopic disease

Novel nucleoside-analogue inhibitor of RNAP shows promising preclinical antibacterial activity

FDA approves Bristol-Myers Squibb's Orencia in psoriatic arthritis

Titan Pharmaceuticals enters CRADA to evaluate ProNeura antimalarial implants

Catalyst Biosciences achieves milestone in ISU ABXIS collaboration

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

Shire submits IND to FDA for SHP-654 as treatment of hemophilia A

Phase I study finds S-55746 active in acute myeloid leukemia and myelodysplastic syndromes

Eli Lilly enters partnership with Purdue University

Shire applies for approval of icatibant in Japan

First report of PML-RARG gene fusion in an acute promyelocytic leukemia patient

Anthera opens European screening for phase III study of Sollpura

Conatus announces Novartis' exclusive license for emricasan is now effective

Novel methionine aminopeptidase 2 inhibitors discovered by SynDevRx

Wake Forest, University College Dublin identify new angiotensin (1-7) analogues

SYGNIS completes Innova acquisition

Padlock Therapeutics patents protein-arginine deiminase type-4 inhibitors

University of Queensland, IOCB present novel HGXPRT inhibitors

Janssen decides not to exercise option to Capricor's CAP-1002 in cardiology

ProMIS Neurosciences receives matching grant for research on antibodies targeting Abeta oligomers

Mission Therapeutics discloses novel ubiquitin carboxyl-terminal hydrolase 30 inhibitors

Puma completes targeted enrollment in phase III trial of neratinib for third-line breast cancer

Endo agrees to voluntarily remove Opana ER from market

PET probe [18F]FEONM images Tau in gliomas

Zoliflodacin to begin phase III development for gonorrhea under new partnership

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...